Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+91%
GBT
Alert Price: $15.85
High Price: $30
Results: 91% in 41 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+55%
EXAS
Alert Price: $15.10
High Price: $23.40
Results: 55% in 37 Days
+38%
EDIT
Alert Price: $18.24
High Price: $25.09
Results: 38% in 55 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

biotech

Trading Lessons

Mainstream Financial News

Archives

Analyst Actions and Breaking News

Follow Us on StockTwits

Overnight Analyst Actions:

Raised:

ILMN Outperform Leerink Partners

Initiates: None

Cuts:

MBLY Neutral Piper Jaffray/Simmons

Overnight Headlines By Ticker:

ABT Abbott Laboratories

3/19 15:47 Late-breaking data shows Abbott’s CardioMEMS HF system is effective in reducing heart failure hospitalizations and cost of care

3/18 12:52 Late-breaking data on Abbott’s MitraClip® System show continued benefit for people with Mitral Regurgitation

ACIA Acacia Communications, Inc

3/20 09:00 Will demonstrate BGA photonic integrated circuit improved RF interface, supports 1.2 Tbps coherent solution

ALQA Alliqua, Inc.

3/20 07:32 Announces the publication of a peer-reviewed Study Examining the Use of MIST Therapy for Deep Tissue Pressure Injuries

AMGN Amgen Inc

3/19 15:48 Presents analyses of PCSK9 inhibitor prescription rejection rates demonstrating significant access barriers for appropriate patients

3/18 13:12 Lowering LDL levels with Repatha (Evolocumab) did not adversely affect cognitive function in Phase 3 Study

AOBC American outdoor Brands (formerly Smith & Wesson)

3/17 16:56 Affirms Q4 adj EPS $0.32-0.42 v $0.37e, R$200-220M v $216Me – March investor presentation

ARTX Arotech Corp

3/20 08:20 Arotech Training and Simulation receives $9.5M U.S. Air Force IDIQ Award With Initial Task Orders Valued at $2.32M

DDD 3-D Systems Corp

3/20 09:02 Unveils Industry’s First Scalable, Fully-Integrated Additive Manufacturing Platform

GLD StreetTracks Gold Trust

3/18 22:31 SPDR Gold Trust ETF daily holdings fall 3.0 tonnes to 834.1 tonnes; 2nd straight decline

ILMN Illumina Inc

3/20 06:09 Leerink Partners Raised ILMN to Outperform from Market Perform, price target: $195

JAZZ Jazz Pharmaceuticals

3/20 09:00 Announces positive results from Phase 3 TONES 3 and TONES 4 studies of JZP-110 in patients with Obstructive Sleep Apnea

MBLY Mobileye NV

3/19 21:56 May seek higher offers from other companies – NY Post citing analyst

3/19 18:48 Piper Jaffray/Simmons Cuts MBLY to Neutral from Overweight, price target: $63.54

NKTR Nektar Therapeutics

3/20 07:30 NKTR-181 meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain

3/20 07:25 Halted: News pending

NVS Novartis AG

3/18 12:45 New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes

OCLR Oclaro, Inc

3/20 07:09 Selected by Ciena to develop 400G Coherent Transponders

OPK Opko Health Inc

3/19 15:40 FDA grants orphan drug designation to Opko drug for treatment of Dravet Syndrome